Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51.
<h4>Background</h4>Pfs25 and Pvs25, surface proteins of mosquito stage of the malaria parasites P. falciparum and P. vivax, respectively, are leading candidates for vaccines preventing malaria transmission by mosquitoes. This single blinded, dose escalating, controlled Phase 1 study asse...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2008-07-01
|
| Series: | PLoS ONE |
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/18612426/?tool=EBI |
| _version_ | 1818722723590832128 |
|---|---|
| author | Yimin Wu Ruth D Ellis Donna Shaffer Erica Fontes Elissa M Malkin Siddhartha Mahanty Michael P Fay David Narum Kelly Rausch Aaron P Miles Joan Aebig Andrew Orcutt Olga Muratova Guanhong Song Lynn Lambert Daming Zhu Kazutoyo Miura Carole Long Allan Saul Louis H Miller Anna P Durbin |
| author_facet | Yimin Wu Ruth D Ellis Donna Shaffer Erica Fontes Elissa M Malkin Siddhartha Mahanty Michael P Fay David Narum Kelly Rausch Aaron P Miles Joan Aebig Andrew Orcutt Olga Muratova Guanhong Song Lynn Lambert Daming Zhu Kazutoyo Miura Carole Long Allan Saul Louis H Miller Anna P Durbin |
| author_sort | Yimin Wu |
| collection | DOAJ |
| description | <h4>Background</h4>Pfs25 and Pvs25, surface proteins of mosquito stage of the malaria parasites P. falciparum and P. vivax, respectively, are leading candidates for vaccines preventing malaria transmission by mosquitoes. This single blinded, dose escalating, controlled Phase 1 study assessed the safety and immunogenicity of recombinant Pfs25 and Pvs25 formulated with Montanide ISA 51, a water-in-oil emulsion.<h4>Methodology/principal findings</h4>The trial was conducted at The Johns Hopkins Center for Immunization Research, Washington DC, USA, between May 16, 2005-April 30, 2007. The trial was designed to enroll 72 healthy male and non-pregnant female volunteers into 1 group to receive adjuvant control and 6 groups to receive escalating doses of the vaccines. Due to unexpected reactogenicity, the vaccination was halted and only 36 volunteers were enrolled into 4 groups: 3 groups of 10 volunteers each were immunized with 5 microg of Pfs25/ISA 51, 5 microg of Pvs25/ISA 51, or 20 microg of Pvs25/ISA 51, respectively. A fourth group of 6 volunteers received adjuvant control (PBS/ISA 51). Frequent local reactogenicity was observed. Systemic adverse events included two cases of erythema nodosum considered to be probably related to the combination of the antigen and the adjuvant. Significant antibody responses were detected in volunteers who completed the lowest scheduled doses of Pfs25/ISA 51. Serum anti-Pfs25 levels correlated with transmission blocking activity.<h4>Conclusion/significance</h4>It is feasible to induce transmission blocking immunity in humans using the Pfs25/ISA 51 vaccine, but these vaccines are unexpectedly reactogenic for further development. This is the first report that the formulation is associated with systemic adverse events including erythema nodosum.<h4>Trial registration</h4>ClinicalTrials.gov NCT00295581. |
| first_indexed | 2024-12-17T20:59:10Z |
| format | Article |
| id | doaj.art-505909db3b03441eaf9a36aa2240a11a |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-17T20:59:10Z |
| publishDate | 2008-07-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-505909db3b03441eaf9a36aa2240a11a2022-12-21T21:32:47ZengPublic Library of Science (PLoS)PLoS ONE1932-62032008-07-0137e263610.1371/journal.pone.0002636Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51.Yimin WuRuth D EllisDonna ShafferErica FontesElissa M MalkinSiddhartha MahantyMichael P FayDavid NarumKelly RauschAaron P MilesJoan AebigAndrew OrcuttOlga MuratovaGuanhong SongLynn LambertDaming ZhuKazutoyo MiuraCarole LongAllan SaulLouis H MillerAnna P Durbin<h4>Background</h4>Pfs25 and Pvs25, surface proteins of mosquito stage of the malaria parasites P. falciparum and P. vivax, respectively, are leading candidates for vaccines preventing malaria transmission by mosquitoes. This single blinded, dose escalating, controlled Phase 1 study assessed the safety and immunogenicity of recombinant Pfs25 and Pvs25 formulated with Montanide ISA 51, a water-in-oil emulsion.<h4>Methodology/principal findings</h4>The trial was conducted at The Johns Hopkins Center for Immunization Research, Washington DC, USA, between May 16, 2005-April 30, 2007. The trial was designed to enroll 72 healthy male and non-pregnant female volunteers into 1 group to receive adjuvant control and 6 groups to receive escalating doses of the vaccines. Due to unexpected reactogenicity, the vaccination was halted and only 36 volunteers were enrolled into 4 groups: 3 groups of 10 volunteers each were immunized with 5 microg of Pfs25/ISA 51, 5 microg of Pvs25/ISA 51, or 20 microg of Pvs25/ISA 51, respectively. A fourth group of 6 volunteers received adjuvant control (PBS/ISA 51). Frequent local reactogenicity was observed. Systemic adverse events included two cases of erythema nodosum considered to be probably related to the combination of the antigen and the adjuvant. Significant antibody responses were detected in volunteers who completed the lowest scheduled doses of Pfs25/ISA 51. Serum anti-Pfs25 levels correlated with transmission blocking activity.<h4>Conclusion/significance</h4>It is feasible to induce transmission blocking immunity in humans using the Pfs25/ISA 51 vaccine, but these vaccines are unexpectedly reactogenic for further development. This is the first report that the formulation is associated with systemic adverse events including erythema nodosum.<h4>Trial registration</h4>ClinicalTrials.gov NCT00295581.https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/18612426/?tool=EBI |
| spellingShingle | Yimin Wu Ruth D Ellis Donna Shaffer Erica Fontes Elissa M Malkin Siddhartha Mahanty Michael P Fay David Narum Kelly Rausch Aaron P Miles Joan Aebig Andrew Orcutt Olga Muratova Guanhong Song Lynn Lambert Daming Zhu Kazutoyo Miura Carole Long Allan Saul Louis H Miller Anna P Durbin Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51. PLoS ONE |
| title | Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51. |
| title_full | Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51. |
| title_fullStr | Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51. |
| title_full_unstemmed | Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51. |
| title_short | Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51. |
| title_sort | phase 1 trial of malaria transmission blocking vaccine candidates pfs25 and pvs25 formulated with montanide isa 51 |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/18612426/?tool=EBI |
| work_keys_str_mv | AT yiminwu phase1trialofmalariatransmissionblockingvaccinecandidatespfs25andpvs25formulatedwithmontanideisa51 AT ruthdellis phase1trialofmalariatransmissionblockingvaccinecandidatespfs25andpvs25formulatedwithmontanideisa51 AT donnashaffer phase1trialofmalariatransmissionblockingvaccinecandidatespfs25andpvs25formulatedwithmontanideisa51 AT ericafontes phase1trialofmalariatransmissionblockingvaccinecandidatespfs25andpvs25formulatedwithmontanideisa51 AT elissammalkin phase1trialofmalariatransmissionblockingvaccinecandidatespfs25andpvs25formulatedwithmontanideisa51 AT siddharthamahanty phase1trialofmalariatransmissionblockingvaccinecandidatespfs25andpvs25formulatedwithmontanideisa51 AT michaelpfay phase1trialofmalariatransmissionblockingvaccinecandidatespfs25andpvs25formulatedwithmontanideisa51 AT davidnarum phase1trialofmalariatransmissionblockingvaccinecandidatespfs25andpvs25formulatedwithmontanideisa51 AT kellyrausch phase1trialofmalariatransmissionblockingvaccinecandidatespfs25andpvs25formulatedwithmontanideisa51 AT aaronpmiles phase1trialofmalariatransmissionblockingvaccinecandidatespfs25andpvs25formulatedwithmontanideisa51 AT joanaebig phase1trialofmalariatransmissionblockingvaccinecandidatespfs25andpvs25formulatedwithmontanideisa51 AT andreworcutt phase1trialofmalariatransmissionblockingvaccinecandidatespfs25andpvs25formulatedwithmontanideisa51 AT olgamuratova phase1trialofmalariatransmissionblockingvaccinecandidatespfs25andpvs25formulatedwithmontanideisa51 AT guanhongsong phase1trialofmalariatransmissionblockingvaccinecandidatespfs25andpvs25formulatedwithmontanideisa51 AT lynnlambert phase1trialofmalariatransmissionblockingvaccinecandidatespfs25andpvs25formulatedwithmontanideisa51 AT damingzhu phase1trialofmalariatransmissionblockingvaccinecandidatespfs25andpvs25formulatedwithmontanideisa51 AT kazutoyomiura phase1trialofmalariatransmissionblockingvaccinecandidatespfs25andpvs25formulatedwithmontanideisa51 AT carolelong phase1trialofmalariatransmissionblockingvaccinecandidatespfs25andpvs25formulatedwithmontanideisa51 AT allansaul phase1trialofmalariatransmissionblockingvaccinecandidatespfs25andpvs25formulatedwithmontanideisa51 AT louishmiller phase1trialofmalariatransmissionblockingvaccinecandidatespfs25andpvs25formulatedwithmontanideisa51 AT annapdurbin phase1trialofmalariatransmissionblockingvaccinecandidatespfs25andpvs25formulatedwithmontanideisa51 |